

Press Release

CureVac's CEO, Ingmar Hoerr, Appointed by European Commission to *High Level Group*

TÜBINGEN, Germany, January 20, 2017 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that the European Commission has appointed CureVac's CEO, Ingmar Hoerr, Ph.D., as one of 15 members of the new *High Level Group* that will advise the Commission on how to strengthen support for breakthrough, market-creating innovation in Horizon 2020 and future research and innovation programs.

The *High Level Group* of Innovators brings together leading personalities from across Europe with a wide range of expertise in business innovation, including entrepreneurs, CEOs, investors and other major players in the innovation ecosystem.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated: "It is a tremendous honor to be selected by the European Commission as member of the *High Level Group* focused on advancing innovation throughout the European Union. As one of the pioneering companies in mRNA therapeutics, CureVac is at the forefront of medical innovation, and I am delighted that our experience and leadership will benefit the next generation of European entrepreneurs who are seeking to improve the world through science."

Read the press release of the European Commission [here](#).

About CureVac AG

Founded in 2000 as a spin-off from the University of Tübingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical Company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

Since its inception, strongly backed by SAP founder Dietmar Hopp's divvini CureVac has received approximately \$370 million (€355 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of \$ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment of an industrial scale production.

For more information, please visit www.curevac.com.

Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756
communications@curevac.com

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694
amielach@tiberend.com